Feng Y - Search Results

1

High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.

Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC. Feng Y, et al. J Thorac Oncol. 2014 May;9(5):646-53. doi: 10.1097/JTO.0000000000000145. J Thorac Oncol. 2014. PMID: 24722154 Free article.

2

MET signaling: novel targeted inhibition and its clinical development in lung cancer.

Feng Y, Thiagarajan PS, Ma PC. Feng Y, et al. J Thorac Oncol. 2012 Feb;7(2):459-67. doi: 10.1097/JTO.0b013e3182417e44. J Thorac Oncol. 2012. PMID: 22237263 Free article. Review.

3

Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer.

Feng Y, Ma PC. Feng Y, et al. Cancer Discov. 2011 Dec;1(7):550-4. doi: 10.1158/2159-8290.CD-11-0289. Cancer Discov. 2011. PMID: 22586678

4

ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.

Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, Feng Y, Ma PC, Arrossi VA, Pennell NA, Tubbs RR. Minca EC, et al. Among authors: feng y. J Mol Diagn. 2013 May;15(3):341-6. doi: 10.1016/j.jmoldx.2013.01.004. Epub 2013 Mar 13. J Mol Diagn. 2013. PMID: 23499337 Free article.

5

Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.

Feng Y, Singh AD, Lanigan C, Tubbs RR, Ma PC. Feng Y, et al. J Thorac Oncol. 2013 Dec;8(12):e109-11. doi: 10.1097/01.JTO.0000437502.82078.9b. J Thorac Oncol. 2013. PMID: 24389446 Free article. No abstract available.

6

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.

Thiagarajan PS, Wu X, Zhang W, Shi I, Bagai R, Leahy P, Feng Y, Veigl M, Lindner D, Danielpour D, Yin L, Rosell R, Bivona TG, Zhang Z, Ma PC. Thiagarajan PS, et al. Among authors: feng y. Oncotarget. 2016 Dec 13;7(50):82013-82027. doi: 10.18632/oncotarget.13307. Oncotarget. 2016. PMID: 27852038 Free PMC article.

7

MET targeted therapy for lung cancer: clinical development and future directions.

Feng Y, Ma PC. Feng Y, et al. Lung Cancer (Auckl). 2012 Aug 9;3:53-67. doi: 10.2147/LCTT.S23423. eCollection 2012. Lung Cancer (Auckl). 2012. PMID: 28210125 Free PMC article. Review.

8

High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.

Hashemi Sadraei N, Feng Y, Du L, Fu P, Haque S, Dowlati A, Gollamudi J, Pennell NA, Mekhail T, Avril S, Farver C, Gerson SL, Sharma N. Hashemi Sadraei N, et al. Among authors: feng y. Lung Cancer. 2018 Dec;126:48-54. doi: 10.1016/j.lungcan.2018.08.011. Epub 2018 Aug 13. Lung Cancer. 2018. PMID: 30527192

9

FERMT1 promotes cell migration and invasion in non-small cell lung cancer via regulating PKP3-mediated activation of p38 MAPK signaling.

Liu B, Feng Y, Xie N, Yang Y, Yang D. Liu B, et al. Among authors: feng y. BMC Cancer. 2024 Jan 10;24(1):58. doi: 10.1186/s12885-023-11812-3. BMC Cancer. 2024. PMID: 38200443 Free PMC article.

10

A Clinical Study on Microwave Ablation in Combination with Chemotherapy in Treating Peripheral IIIB-IV Non-Small Cell Lung Cancer.

Zhang YQ, Wu YL, Feng Y, Zhou YX. Zhang YQ, et al. Among authors: feng y. Cancer Biother Radiopharm. 2022 Mar;37(2):141-146. doi: 10.1089/cbr.2020.3859. Epub 2020 Aug 19. Cancer Biother Radiopharm. 2022. PMID: 32822222 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26,726 results

Search Page

Filters